To test translational relevance of the 39-gene signature, we applied it to a publicly available dataset that prospectively tracked outcomes of ER+, Her2-negative breast cancers following neoadjuvant taxane-anthracycline chemotherapy (23) (Figure 3, B–E). This evidence concerns the gene ERBB2 and breast cancer.